Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Court Judgment Challenges Status of Standards: How Will It Hit Medtech?

Executive Summary

An EU legal judgment in the construction industry is changing the standards game. Until now, there has not been an official link between standards and EU law. That has changed. But how is medtech affected?

You may also be interested in...



Will New EU Standards Crisis Management Disrupt Industry's MDR Efforts?

Some of the EU's most critical medtech standards have been coming under criticism for more than half a decade. Now, the European Commission is making key changes, but the timing could not be worse for the sector.

EU Standards Bodies' Call For Talks, End To Financial Threat

European standards bodies are reacting to the European Court of Justice recent ruling in a construction-industry case that the groups say could undermine the effectiveness and the financing of EU standards.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel